<DOC>
	<DOC>NCT02070575</DOC>
	<brief_summary>The purpose of this study is to investigate if a new blood test looking at PSA and a group of PSA related proteins in a patient's blood can indicate which men after surgery with a rising PSA could benefit from treatment, and/or indicate which men are at higher risk for recurrence before initial treatment is given.</brief_summary>
	<brief_title>Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Kallikreins</mesh_term>
	<criteria>All patients treated with radical prostatectomy that develop a rising serum PSA ≥ 0.05ng/ml and have not received any kind of additional therapy. Patients who have had additional therapy post radical prostatectomy are eligible for this study if ≥1 year has passed since treatment and the patient develops a rising serum PSA ≥0.05ng/ml. Previous additional therapy for prostate cancer, less than 1 year ago No evidence of rising PSA Patients unwilling to undergo venesection</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PSA</keyword>
	<keyword>Human Kallikrein 2</keyword>
	<keyword>locally resected prostate cancer</keyword>
	<keyword>biochemical recurrence</keyword>
	<keyword>14-041</keyword>
</DOC>